Date of Award
Chemistry and Biochemistry
Fibrinolysis, Rivaroxaban, TAFI
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Rivaroxaban is a direct factor Xa inhibitor, recently implemented as a favorable alternative to warfarin in anticoagulation therapy. Rivaroxaban effectively reduces thrombin generation, which plays a major role in the activation of thrombin activatable fibrinolysis inhibitor (TAFI). Activated TAFI (TAFIa) has an antifibrinolytic role and therefore we hypothesized that rivaroxaban would induce more rapid clot lysis. In vitro clot lysis assays were used to explore this hypothesis. Additionally, these assays were used to determine if the profibrinolytic effects of rivaroxaban could be modulated by TAFI levels or a stabilizing T325I TAFI polymorphism. Rivaroxaban was shown to decrease thrombin generation, resulting in less TAFI activation, thus enhancing lysis. These effects were also shown to be less substantial in the presence of greater TAFI levels or the more stable I325 protein. These findings suggest a role for TAFI levels and the T325I polymorphism in the pharmacodynamics and pharmacogenomics of rivaroxaban.
Garabon, Justin John William, "Impact of Thrombomodulin and Thrombin-Activatable Fibrinolysis Inhibitor on the Anticoagulant and Profibrinolytic Effects of Rivaroxaban" (2016). Electronic Theses and Dissertations. 5822.